Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
3036-A PREVENTION OF MORTALITY WITH LONG-TERM HUMAN ALBUMIN ADMINISTRATION IN PATIENTS WITH DECOMPENSATED CIRRHOSIS AND ASCITES: DESIGN AND STATUS OF THE PRECIOSA STUDY Tarek Hassanein 1 , Paolo Angeli 2 , Wim Laleman 3 , Tamara Milanovic 4 , Gergana Taneva 5 , Mireia Torres 6 , Peter Nelson 6 , Javier Fernandez 7,8 and On behalf of the PRECIOSA Study Investigators, (1)Southern California Research Center, (2)Padua Hospital University, (3)University Hospital Gasthuisberg, KU Leuven, (4)University Clinical Center of Serbia, (5)Saint Sophia Medical College, (6)Grifols, (7)Hospital Clnic, Idibaps and Ciberehd, (8)EF Clif, Easl-Clif Consortium and Grifols Chair Background: Patients with decompensated cirrhosis develop ascites, variceal bleeding, hepatic encephalopathy, and bacterial infections, complications associated with worse survival compared to compensated cirrhosis
Clinical outcomes matter
References & Links Di Lullo G, Sweeney S, Korkko J, Ala-Kokko L, San Antonio J
Additionally, 59% have vomiting
Leveren er det strste reservoaret for glutation, som er av strste vekt ved leverens avgiftningsfunksjoner i fase I og fase II
Vigilant comprehensive analysis of published cases and recognition of new ones may be helpful in establishing definite classification and proposing clinical features that would facilitate its early diagnosis, as a prerequisite for timely treatment and better prognosis of this rare pathology
